Korro Bio, Inc.

Korro Bio, Inc.

Korro Bio operates as a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. It was formed around foundational intellectual property from MIT and the Broad Institute, focusing on oligonucleotide-directed RNA editing. The company went public via a reverse merger with Frequency Therapeutics in November 2023 and trades on Nasdaq under the symbol KRRO. Its lead programs target Alpha-1 Antitrypsin Deficiency (AATD) and other severe liver, central nervous system, and retinal diseases where transient, precise RNA editing offers a therapeutic window. The company's OPERA platform uses synthetic oligonucleotides to recruit endogenous Adenosine Deaminase Acting on RNA (ADAR) enzymes, enabling site-specific adenosine-to-inosine (A-to-I) editing. This mechanism corrects single-point mutations at the mRNA level without inducing double-strand DNA breaks. Korro's pipeline includes KRRO-110 for AATD, which received FDA Orphan Drug Designation, and a broader discovery portfolio spanning CNS indications such as ALS and Huntington's disease. The firm has disclosed preclinical collaborations and a partnership with the Broad Institute to expand its editing window through novel guide chemistries. Its geographic footprint is concentrated in the United States, with all R&D operations in the Cambridge biotech cluster. Post-merger in late 2023, Korro Bio held over $170 million in cash and equivalents, providing runway into 2026. The company is led by CEO Ram Aiyar, a former Novartis executive, alongside a team with deep experience in RNA biology from Biogen, Alnylam, and Moderna. The firm maintains research collaborations with the Broad Institute and academic centers, but does not operate adjacent investment arms, philanthropic foundations, or wealth-origin vehicles — it is a traditional drug-development company funded by public equity and institutional investors. In 2024, Korro presented preclinical data demonstrating durable editing of the SERPINA1 transcript, advancing its AATD lead toward an Investigational New Drug (IND) filing. Korro Bio's structural differentiator is its reliance on recruiting naturally occurring ADAR enzymes rather than delivering an exogenous gene-editing protein like CRISPR-associated nucleases. This avoids immunogenicity concerns tied to prolonged expression of foreign proteins and sidesteps the regulatory complexity of permanent genomic changes. The platform's reversibility and tissue-specific delivery, primarily through lipid nanoparticles and conjugates, position it adjacent to — but distinct from — the permanent DNA-editing companies dominating the precision-medicine landscape.